Published in Pharmacogenomics J on June 15, 2010
CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial. J Natl Cancer Inst (2012) 5.27
CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients. J Natl Cancer Inst (2012) 4.54
Inducible nitric oxide synthase drives mTOR pathway activation and proliferation of human melanoma by reversible nitrosylation of TSC2. Cancer Res (2014) 0.90
Genotyping concordance in DNA extracted from formalin-fixed paraffin embedded (FFPE) breast tumor and whole blood for pharmacogenetic analyses. Mol Oncol (2015) 0.79
Genetic Testing and Tissue Banking for Personalized Oncology: Analytical and Institutional Factors. Semin Oncol (2015) 0.75
Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol (2005) 6.90
CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst (2005) 5.92
PCR amplification from paraffin-embedded tissues. Effects of fixative and fixation time. Am J Clin Pathol (1991) 4.65
The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype. Clin Pharmacol Ther (2007) 4.33
Real-time PCR analysis of DNA and RNA extracted from formalin-fixed and paraffin-embedded biopsies. Methods (2001) 4.04
Quantitative mRNA expression analysis from formalin-fixed, paraffin-embedded tissues using 5' nuclease quantitative reverse transcription-polymerase chain reaction. J Mol Diagn (2000) 3.59
Towards quantitative mRNA analysis in paraffin-embedded tissues using real-time reverse transcriptase-polymerase chain reaction: a methodological study on lymph nodes from melanoma patients. J Mol Diagn (2003) 2.41
A multiplex PCR predictor for aCGH success of FFPE samples. Br J Cancer (2006) 2.33
RNA expression analysis from formalin fixed paraffin embedded tissues. Histochem Cell Biol (2008) 2.13
Cytochrome P450 2D6 activity predicts discontinuation of tamoxifen therapy in breast cancer patients. Pharmacogenomics J (2009) 1.43
Genotyping for polymorphic drug metabolizing enzymes from paraffin-embedded and immunohistochemically stained tumor samples. Pharmacogenetics (2003) 1.39
Application of array CGH on archival formalin-fixed paraffin-embedded tissues including small numbers of microdissected cells. Lab Invest (2006) 1.35
High quality copy number and genotype data from FFPE samples using Molecular Inversion Probe (MIP) microarrays. BMC Med Genomics (2009) 1.29
Real-time quantitative RT-PCR shows variable, assay-dependent sensitivity to formalin fixation: implications for direct comparison of transcript levels in paraffin-embedded tissues. Diagn Mol Pathol (2006) 1.28
Lack of involvement of nucleotide excision repair gene polymorphisms in colorectal cancer. Br J Cancer (2003) 1.23
Genotyping using the TaqMan assay. Curr Protoc Hum Genet (2008) 1.22
Feasibility of using decades-old archival tissues in molecular oncology/epidemiology. Am J Pathol (1996) 1.09
Analysis of angiogenesis genes from paraffin-embedded breast tumor and lymph nodes. Breast Cancer Res Treat (2006) 1.04
Loss of heterozygosity studies revisited: prior quantification of the amplifiable DNA content of archival samples improves efficiency and reliability. J Mol Diagn (2002) 1.04
Multiplex PCR with minisequencing as an effective high-throughput SNP typing method for formalin-fixed tissue. Electrophoresis (2007) 1.02
An efficient method for the assessment of DNA quality of archival microdissected specimens. Mod Pathol (2002) 1.01
Concordance of pharmacogenetic polymorphisms in tumor and germ line DNA in adult patients with acute myeloid leukemia. Cancer Epidemiol Biomarkers Prev (2007) 1.01
Concordance of pharmacogenetic markers in germline and colorectal tumor DNA. Pharmacogenomics (2005) 1.00
Accurate genotyping from paraffin-embedded normal tissue adjacent to breast cancer. Carcinogenesis (2005) 0.97
MALDI-TOF MS and TaqMan assisted SNP genotyping of DNA isolated from formalin-fixed and paraffin-embedded tissues (FFPET). Hum Mutat (2005) 0.93
The applicability of formalin-fixed and formalin fixed paraffin embedded tissues in forensic DNA analysis. J Forensic Sci (1997) 0.92
Optimisation and validation of methods to assess single nucleotide polymorphisms (SNPs) in archival histological material. Radiother Oncol (2004) 0.81
Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet (2005) 11.05
Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet (2011) 10.62
Body mass index, serum sex hormones, and breast cancer risk in postmenopausal women. J Natl Cancer Inst (2003) 6.20
Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet (1998) 5.35
Role of the mouse ank gene in control of tissue calcification and arthritis. Science (2000) 4.43
A "quickscore" method for immunohistochemical semiquantitation: validation for oestrogen receptor in breast carcinomas. J Clin Pathol (1995) 3.79
Early neonatal death in mice homozygous for a null allele of the insulin receptor gene. Nat Genet (1996) 3.40
Hormonal impact of the 17alpha-hydroxylase/C(17,20)-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer. Br J Cancer (2004) 3.32
Pharmacology of novel steroidal inhibitors of cytochrome P450(17) alpha (17 alpha-hydroxylase/C17-20 lyase). J Steroid Biochem Mol Biol (1994) 3.19
Correlation between immunohistochemistry (HercepTest) and fluorescence in situ hybridization (FISH) for HER-2 in 426 breast carcinomas from 37 centres. J Pathol (2003) 3.14
Construction and characterization of a retroviral vector demonstrating efficient expression of cloned cDNA sequences. DNA (1988) 2.61
Effectiveness of the California 1990-1991 tobacco education media campaign. Am J Prev Med (1995) 2.45
Biologic markers as predictors of clinical outcome from systemic therapy for primary operable breast cancer. J Clin Oncol (1999) 2.32
Captopril inhibits angiogenesis and slows the growth of experimental tumors in rats. J Clin Invest (1996) 2.24
Circulating sex hormones and breast cancer risk factors in postmenopausal women: reanalysis of 13 studies. Br J Cancer (2011) 2.20
Inhibition of mammary duct development but not alveolar outgrowth during pregnancy in transgenic mice expressing active TGF-beta 1. Genes Dev (1993) 2.13
T cell development in mice that lack the zeta chain of the T cell antigen receptor complex. Science (1993) 2.06
Changes in estrogen receptor, progesterone receptor, and pS2 expression in tamoxifen-resistant human breast cancer. Cancer Res (1995) 2.05
Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet (2015) 2.05
Use of the aromatase inhibitor 4-hydroxyandrostenedione in postmenopausal breast cancer: optimization of therapeutic dose and route. Cancer Res (1987) 2.03
A polygenic model for the evolution and maintenance of conditional strategies. Proc Biol Sci (1990) 1.98
Prognostic indices for survival during postcardiotomy intra-aortic balloon pumping. Methods of scoring and classification, with implications for left ventricular assist device utilization. J Thorac Cardiovasc Surg (1977) 1.96
Biochemistry and pharmacokinetics of potent non-steroidal cytochrome P450(17alpha) inhibitors. J Steroid Biochem Mol Biol (1997) 1.94
Breast-cancer osteolysis, bone metastases, and anti-osteolytic effect of aspirin. Lancet (1976) 1.92
Overproduction of protein kinase C causes disordered growth control in rat fibroblasts. Cell (1988) 1.91
Best Practice No 176: Updated recommendations for HER2 testing in the UK. J Clin Pathol (2004) 1.90
Toxicogenomics-based discrimination of toxic mechanism in HepG2 human hepatoma cells. Toxicol Sci (2000) 1.87
Benefit from adjuvant tamoxifen therapy in primary breast cancer patients according oestrogen receptor, progesterone receptor, EGF receptor and HER2 status. Ann Oncol (2006) 1.85
Continuous spinal anesthesia with combined hyperbaric and isobaric bupivacaine in a patient with scoliosis. Anesth Analg (1990) 1.80
A pilot trial to evaluate the acute toxicity and feasibility of tamoxifen for prevention of breast cancer. Br J Cancer (1989) 1.78
Elevated content of the tyrosine kinase substrate phospholipase C-gamma 1 in primary human breast carcinomas. Proc Natl Acad Sci U S A (1991) 1.77
Cryptophyte algae are robbed of their organelles by the marine ciliate Mesodinium rubrum. Nature (2000) 1.77
Induction of transforming growth factor beta 1 in human breast cancer in vivo following tamoxifen treatment. Cancer Res (1992) 1.71
Rifampin is a selective, pleiotropic inducer of drug metabolism genes in human hepatocytes: studies with cDNA and oligonucleotide expression arrays. J Pharmacol Exp Ther (2001) 1.64
Comparison of new immunohistochemical assay for oestrogen receptor in paraffin wax embedded breast carcinoma tissue with quantitative enzyme immunoassay. J Clin Pathol (1994) 1.62
Isolation of cDNA clones encoding protein kinase C: evidence for a protein kinase C-related gene family. Proc Natl Acad Sci U S A (1987) 1.59
Role of insulin-like growth factors and the type I insulin-like growth factor receptor in the estrogen-stimulated proliferation of human breast cancer cells. J Biol Chem (1990) 1.57
Acquired tamoxifen resistance in human breast cancer and reduced intra-tumoral drug concentration. Lancet (1994) 1.49
Contig assembly of bacterial artificial chromosome clones through multiplexed fluorescence-labeled fingerprinting. Genomics (1999) 1.48
Identification of VEGF-regulated genes associated with increased lung metastatic potential: functional involvement of tenascin-C in tumor growth and lung metastasis. Oncogene (2008) 1.48
Detection of circulating epithelial cells in the blood of patients with breast cancer: comparison of three techniques. Br J Cancer (2005) 1.48
Response to specific anti-oestrogen (ICI182780) in tamoxifen-resistant breast cancer. Lancet (1995) 1.47
Apoptosis and proliferation as predictors of chemotherapy response in patients with breast carcinoma. Cancer (2000) 1.45
A SNP in steroid receptor coactivator-1 disrupts a GSK3β phosphorylation site and is associated with altered tamoxifen response in bone. Mol Endocrinol (2011) 1.45
Suppression of ovarian function in combination with an aromatase inhibitor as treatment for advanced breast cancer in pre-menopausal women. Eur J Cancer (2010) 1.43
Sex hormones and risk of breast cancer in premenopausal women: a collaborative reanalysis of individual participant data from seven prospective studies. Lancet Oncol (2013) 1.43
Investigation of a new pure antiestrogen (ICI 182780) in women with primary breast cancer. Cancer Res (1994) 1.43
Cesarean delivery in a patient with a transplanted heart. Anesthesiology (1989) 1.41
HER-2 amplification impedes the antiproliferative effects of hormone therapy in estrogen receptor-positive primary breast cancer. Cancer Res (2001) 1.41
Phase I study of the oral nonsteroidal aromatase inhibitor CGS 20267 in healthy postmenopausal women. J Clin Endocrinol Metab (1993) 1.41
Gonadotropin-releasing hormone analogue (goserelin) plus hormone replacement therapy for the treatment of endometriosis: a randomized controlled trial. Fertil Steril (1995) 1.41
Recommendations for HER2 testing in the UK. J Clin Pathol (2000) 1.41
Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer. Br J Cancer (1996) 1.40
Five-color-based high-information-content fingerprinting of bacterial artificial chromosome clones using type IIS restriction endonucleases. Genomics (2001) 1.40
Poor response to oral ciprofloxacin in the treatment of peritonitis in patients on intermittent peritoneal dialysis. Perit Dial Int (1993) 1.40
Discordance between core needle biopsy (CNB) and excisional biopsy (EB) for estrogen receptor (ER), progesterone receptor (PgR) and HER2 status in early breast cancer (EBC). Ann Oncol (2009) 1.40
Reduced apoptosis and proliferation and increased Bcl-2 in residual breast cancer following preoperative chemotherapy. Breast Cancer Res Treat (1998) 1.39
Precordial Doppler monitoring and pulse oximetry during cesarean delivery: detection of venous air embolism. Reg Anesth (1991) 1.39
The difficult airway in obstetric anesthesia: techniques for airway management and the role of regional anesthesia. J Clin Anesth (1988) 1.39
A new treatment for endometriosis. Lancet (1989) 1.38
An alternative to pinprick testing. Reg Anesth (1992) 1.38
4-Hydroxyandrostenedione in treatment of postmenopausal patients with advanced breast cancer. Lancet (1984) 1.35
Hydrocortisone alone vs hydrocortisone plus aminoglutethimide: a comparison of the endocrine effects in postmenopausal breast cancer. Eur J Cancer Clin Oncol (1984) 1.34
A germline mutation in the androgen receptor gene in two brothers with breast cancer and Reifenstein syndrome. Nat Genet (1992) 1.34
Increased activator protein-1 DNA binding and c-Jun NH2-terminal kinase activity in human breast tumors with acquired tamoxifen resistance. Clin Cancer Res (1999) 1.32
Efficient studies of long-distance Bmp5 gene regulation using bacterial artificial chromosomes. Proc Natl Acad Sci U S A (2000) 1.31
In vivo inhibition of aromatization by exemestane, a novel irreversible aromatase inhibitor, in postmenopausal breast cancer patients. Clin Cancer Res (1998) 1.31
Preoperative chemotherapy induces apoptosis in early breast cancer. Lancet (1997) 1.31
Cyclooxygenase-2 (COX-2), aromatase and breast cancer: a possible role for COX-2 inhibitors in breast cancer chemoprevention. Ann Oncol (2002) 1.30
Studies on the pathogenesis of type I (distal) renal tubular acidosis as revealed by the urinary PCO2 tensions. J Clin Invest (1974) 1.30
Dual regulation of proliferation and apoptosis: c-myc in bitransgenic murine mammary tumor models. Oncogene (2000) 1.29
Do anti-smoking media campaigns help smokers quit? Public Health Rep (1993) 1.29
Targeted disruption of the Hexa gene results in mice with biochemical and pathologic features of Tay-Sachs disease. Proc Natl Acad Sci U S A (1994) 1.28
1L-myo-inositol-1-phosphate synthase. Biochim Biophys Acta (1997) 1.26
A prospective study of endogenous serum hormone concentrations and breast cancer risk in post-menopausal women on the island of Guernsey. Br J Cancer (1997) 1.26
Endocrine and therapeutic effects of aminoglutethimide in premenopausal patients with breast cancer. J Clin Endocrinol Metab (1982) 1.25
A prospective study of endogenous serum hormone concentrations and breast cancer risk in premenopausal women on the island of Guernsey. Br J Cancer (1997) 1.25
Targeting the receptor tyrosine kinase RET sensitizes breast cancer cells to tamoxifen treatment and reveals a role for RET in endocrine resistance. Oncogene (2010) 1.25
Aminoglutethimide dose and hormone suppression in advanced breast cancer. Eur J Cancer Clin Oncol (1983) 1.25
Caution: Vaginal estradiol appears to be contraindicated in postmenopausal women on adjuvant aromatase inhibitors. Ann Oncol (2006) 1.23
Expression of transforming growth factor-beta 1, -beta 2, and -beta 3 mRNA and protein in the murine lung. Am J Respir Cell Mol Biol (1991) 1.23
HER2 testing in the UK: further update to recommendations. J Clin Pathol (2008) 1.22
Molecular cloning of TPAR1, a gene whose expression is repressed by the tumor promoter 12-O-tetradecanoylphorbol 13-acetate (TPA). Exp Cell Res (1994) 1.20
Early changes in apoptosis and proliferation following primary chemotherapy for breast cancer. Br J Cancer (2003) 1.18
Prediction of response to neoadjuvant chemoendocrine therapy in primary breast carcinomas. Clin Cancer Res (1997) 1.17
Immunoreactive calcitonin production by human lung carcinoma cells in culture. Br J Cancer (1975) 1.16
Responsible alcohol service: a study of server, manager, and environmental impact. Am J Public Health (1991) 1.16
Prediction of clinical outcome from primary tamoxifen by expression of biologic markers in breast cancer patients. Clin Cancer Res (2000) 1.16
Endocrine effects of low dose aminoglutethimide alone in advanced postmenopausal breast cancer. Br J Cancer (1983) 1.15
Metalloproteinase inhibition and erythroid potentiation are independent activities of tissue inhibitor of metalloproteinases-1. Blood (1995) 1.14
The biology of neoadjuvant chemotherapy for breast cancer. Endocr Relat Cancer (2002) 1.14
Studies of the potential utility of Ki67 as a predictive molecular marker of clinical response in primary breast cancer. Breast Cancer Res Treat (2003) 1.13